Optimizing Personalized Care Plans for Patients with Advanced Non-Small Cell Lung Cancer
STATEMENT OF NEED An estimated 228,150 new cases of lung cancer are reported in the United States annually, and 142,670 people die of the disease. The major subtypes are non-small ...
STATEMENT OF NEED
An estimated 228,150 new cases of lung cancer are reported in the United States annually, and 142,670 people die of the disease. The major subtypes are non-small cells (84%) and small cells (13%). Most patients with lung cancer are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management. Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop the progressive disease within 5 months of their final cycle. Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine the selection of novel therapies has improved outcomes for some patients. However, the 5-year survival rates remain dismal for both non-small cell (18%) and small cell lung cancer (5% to 10%), indicating a need for continued research on more effective approaches to tumor control.
Oncologists, pathologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).
Upon completion of this activity, participants should be able to:
Assess predictive and prognostic markers that can inform personalized care plans for patients with advanced NSCLC
Evaluate current and emerging data on first-line, second-line, and salvage therapy for patients with advanced NSCLC
Apply strategies to manage adverse events and optimize treatment outcomes of patients with advanced NSCLC
Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.
I'm interested in this
Share with others
Write the first review
Share with others